Table 3 Characteristics and outcome at inclusion (Day 1 of wild-type AmpC-producing Enterobacterales infection)
All population (n = 177) | clinical failure (n = 52) | clinical cure (n = 125) | p | ||||
|---|---|---|---|---|---|---|---|
Nb | Results | Nb | Results | Nb | Results | ||
Number of ICU infection before inclusion | 177 | 0 [0–1] | 52 | 0 [0–1] | 125 | 0 [0–1] | 0.283 |
Time between previous ICU infection and inclusion (days) | 66 | 8 [4–14] | 20 | 8 [6–13] | 46 | 8 [4–16] | 0.742 |
Time between ICU admission and inclusion (days) | 176 | 7 [2–11] | 51 | 7 [4–11] | 125 | 6 [2–11] | 0.155 |
SOFA score at day 0 of infection | 133 | 6 [3–9] | 41 | 8 [5–10] | 92 | 6 [3–8] | 0.014 |
MV during infection | 177 | 144 (81.4%) | 52 | 49 (94.2%) | 125 | 95 (76%) | 0.005 |
Renal replacement therapy during infection | 177 | 38 (21.5%) | 52 | 20 (38.5%) | 125 | 18 (14.4%) | 0.000 |
Urinary catheter during infection | 177 | 171 (96.6%) | 52 | 52 (100%) | 125 | 119 (95.2%) | 0.108 |
Catheter during infection | 177 | 132 (74.6%) | 52 | 46 (88.5%) | 125 | 86 (68.8%) | 0.006 |
Number of catheters | 177 | 2 [0–2] | 52 | 2 [2–2] | 125 | 2 [0–2] | 0.000 |
Catheters at the end of AMB therapy | 177 | 89 (50.3%) | 52 | 35 (67.3%) | 125 | 54 (43.2%) | 0.003 |
Number of catheters at the end of AMB therapy | 177 | 1 [0–2] | 52 | 2 [0–2] | 125 | 0 [0–2] | 0.001 |
Site of wtAE infection | |||||||
Lung | 177 | 132 (74.6%) | 52 | 48 (92.3%) | 125 | 84 (67.2%) | 0.000 |
Ventilator-associated pneumonia | 132 | 123 (93.2%) | 52 | 47 (90.4%) | 125 | 76 (60.8%) | 0.000 |
Skin and Soft tissue | 177 | 14 (7.9%) | 52 | 2 (3.8%) | 125 | 12 (9.6%) | 0.196 |
Abdomen | 177 | 11 (6.2%) | 52 | 1 (1.9%) | 125 | 10 (8%) | 0.127 |
Primary bacteremia | 177 | 5 (2.8%) | 52 | 0 (0%) | 125 | 5 (4%) | 0.143 |
CSF | 177 | 5 (2.8%) | 52 | 0 (0%) | 125 | 5 (4%) | 0.323 |
Others | 177 | 10 (5.6%) | 52 | 1 (1.9%) | 125 | 9 (7.2%) | 0.285 |
Microbiological samples after completion of AMB therapy | 177 | 85 (48%) | 52 | 33 (63.5%) | 125 | 52 (41.6%) | 0.008 |
Microbiological failure | 85 | 27 (31.8%) | 33 | 22 (66.7%) | 52 | 5 (9.6%) | 0.000 |
Overproduced cephalosporinases | 26 | 5 (19.2%) | 33 | 5 (15.2%) | 52 | 0 (0%) | 0.007 |
Recurrent AE infection | 177 | 24 (13.6%) | 52 | 8 (15.4%) | 125 | 16 (12.8%) | 0.647 |
Time to recurrent infection (days) | 28 | 11.5 [5–18] | 5 | 12 [6–21] | 15 | 16 [12–23] | 0.358 |
Recurrent infection with overproduced cephalosporinases | 26 | 3 (15.8%) | 5 | 2 (40%) | 13 | 1 (7.7%) | 0.099 |
New AE infection | 177 | 8 (4.5%) | 52 | 2 (3.8%) | 125 | 6 (4.8%) | 0.781 |
Time between the first and the second AE infection (days) | 8 | 30 [24–48] | 2 | 48 [35–60] | 6 | 30 [26–43] | 0.737 |
Overproduced cephalosporinases | 7 | 2 (28.6%) | 1 | 0 (0%) | 6 | 2 (33.3%) | 0.495 |
Outcome | |||||||
AmpC+ | 177 | 10 (5.6%) | 52 | 7 (13.5%) | 125 | 3 (2.4%) | 0.004 |
Death during ICU stay | 177 | 68 (38.4%) | 52 | 36 (69.2%) | 125 | 32 (25.6%) | 0.000 |
Length of ICU stay (days) | 170 | 23 [14–39] | 52 | 24 [15–32] | 118 | 22 [14–39] | 0.625 |
Death during hospitalization | 177 | 73 (41.2%) | 52 | 38 (73.1%) | 125 | 35 (28%) | 0.000 |
Time between hospitalization and death (days) | 72 | 28 [16–45] | 36 | 21 [13–35] | 36 | 34 [22–48] | 0.006 |
Time between wtAE infection and discharge from ICU (days) | 168 | 17 [8–26] | 51 | 14 [8–26] | 117 | 17 [9–28] | 0.411 |
Death within the first five days of AMB therapy | 176 | 7 (4%) | 51 | 7 (13.7%) | 125 | 0 (0%) | 0.000 |
Withdrawal or withholding of life support | 68 | 40 (58.8%) | 36 | 16 (44.4%) | 32 | 24 (75%) | 0.011 |